Utilizing Nanobody Technology to Target Non-Immunodominant Domains of VAR2CSA
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
Placental malaria is a major health problem for both pregnant women and their fetuses in malaria endemic regions. It is triggered by the accumulation of Plasmodium falciparum-infected erythrocytes (IE) in the intervillous spaces of the placenta and is associated with foetal growth restriction and maternal anemia. IE accumulation is supported by the binding of the parasite-expressed protein VAR2CSA to placental chondroitin sulfate A (CSA). Defining specific CSA-binding epitopes of VAR2CSA, against which to target the immune response, is essential for the development of a vaccine aimed at blocking IE adhesion. However, the development of a VAR2CSA adhesion-blocking vaccine remains challenging due to (i) the large size of VAR2CSA and (ii) the extensive immune selection for polymorphisms and thereby non-neutralizing B-cell epitopes. Camelid heavy-chain-only antibodies (HcAbs) are known to target epitopes that are less immunogenic to classical IgG and, due to their small size and protruding antigen-binding loop, able to reach and recognize cryptic, conformational epitopes which are inaccessible to conventional antibodies. The variable heavy chain (VHH) domain is the antigen-binding site of camelid HcAbs, the so called Nanobody, which represents the smallest known (15 kDa) intact, native antigen-binding fragment. In this study, we have used the Nanobody technology, an approach new to malaria research, to generate small and functional antibody fragments recognizing unique epitopes broadly distributed on VAR2CSA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several nanobodies to DBL1 and ID1–ID2a reduced parasite adhesion to CSA while nanobodies to DBL4, DBL5 and DBL6 had no inhibitory activity [61,62].”
From Designing a VAR2CSA-based vaccine to prevent placental malaria (2015) · cites this paper as [61]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Properties, production, and applications of camelid single-domain antibody fragments
Harmsen, M. M., & De Haard, H. J. (2007) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-007-1142-2 · Cited by 809 · cited 2×
“The CDR regions of Nbs are often longer and more flexible than corresponding regions of conventional antibodies and thus can bind epitopes that physically cannot be targeted by conventional immunoglobulins [28,31,32].”
Salanti, A., Staalsoe, T., Lavstsen, T., Jensen, A. T. R., Sowa, M. P. K., Arnot, D. E., Hviid, L., & Theander, T. G. (2003) · Molecular Microbiology · doi:10.1046/j.1365-2958.2003.03570.x · Cited by 702
Self-citationEvidence for the Involvement of VAR2CSA in Pregnancy-associated Malaria
Salanti, A., Dahlbäck, M., Turner, L., Nielsen, M. A., Barfod, L., Magistrado, P., Jensen, A. T. R., Lavstsen, T., Ofori, M. F., Marsh, K., et al. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20041579 · Cited by 604 · cited 1×
“During subsequent pregnancies, women build up protective immunity to placental malaria by acquiring antiVAR2CSA antibodies that prevent IE binding to CSA in the placenta [6,7].”
Self-citationSingle domain camel antibodies: current status
Muyldermans, S. (2001) · Reviews in Molecular Biotechnology · doi:10.1016/s1389-0352(01)00021-6 · Cited by 552 · cited 1×
“The variable heavy chain (VHH) domain is the antigen-binding site of camelid HcAbs and represents the smallest (15 kDa), intact, native antigenbinding fragment [23].”
Camelid immunoglobulins and nanobody technology
Muyldermans, S., Baral, T. N., Retamozzo, V. C., De Baetselier, P., De Genst, E., Kinne, J., Leonhardt, H., Magez, S., Nguyen, V. K., Revets, H., et al. (2009) · Veterinary Immunology and Immunopathology · doi:10.1016/j.vetimm.2008.10.299 · Cited by 533
Self-citationSingle domain antibodies: promising experimental and therapeutic tools in infection and immunity
Wesolowski, J., Alzogaray, V., Reyelt, J., Unger, M., Juarez, K., Urrutia, M., Cauerhff, A., Danquah, W., Rissiek, B., Scheuplein, F., et al. (2009) · Medical Microbiology and Immunology · doi:10.1007/s00430-009-0116-7 · Cited by 513
Muyldermans, S., Atarhouch, T., Saldanha, J., Barbosa, J. A. R. G., & Hamers, R. (1994) · "Protein Engineering, Design and Selection" · doi:10.1093/protein/7.9.1129 · Cited by 494 · cited 1×
“The CDR regions of Nbs are often longer and more flexible than corresponding regions of conventional antibodies and thus can bind epitopes that physically cannot be targeted by conventional immunoglobulins [28,31,32].”
The Sick Placenta—The Role of Malaria
Brabin, B. J., Romagosa, C., Abdelgalil, S., Menéndez, C., Verhoeff, F. H., McGready, R., Fletcher, K. A., Owens, S., d'Alessandro, U., Nosten, F., et al. (2004) · Placenta · doi:10.1016/j.placenta.2003.10.019 · Cited by 375 · cited 1×
“IE adhesion to the placenta triggers the recruitment and activation of maternal mononuclear cells secreting pro-inflammatory cytokines, leading to further inflammation and negative effects on placental function [4] and fetal development [5].”
β-Lactamase Inhibitors Derived from Single-Domain Antibody Fragments Elicited in the Camelidae
Conrath, K. E., Lauwereys, M., Galleni, M., Matagne, A., Frère, J.-M., Kinne, J., Wyns, L., & Muyldermans, S. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.10.2807-2812.2001 · Cited by 347 · cited 1×
“Construction of the Nanobody library and selection of VAR2CSA-specific Nanobodies The nanobody library was constructed as previously described by Conrath et al, 2001.”
MethodEfficient Targeting of Conserved Cryptic Epitopes of Infectious Agents by Single Domain Antibodies
Stijlemans, B., Conrath, K., Cortez-Retamozo, V., Van Xong, H., Wyns, L., Senter, P., Revets, H., De Baetselier, P., Muyldermans, S., & Magez, S. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m307341200 · Cited by 276
Self-citationDuffy, P. E., & Fried, M. (2003) · Infection and Immunity · doi:10.1128/iai.71.11.6620-6623.2003 · Cited by 260 · cited 1×
“During subsequent pregnancies, women build up protective immunity to placental malaria by acquiring antiVAR2CSA antibodies that prevent IE binding to CSA in the placenta [6,7].”
Structure and Properties of a Complex of α-Synuclein and a Single-Domain Camelid Antibody
De Genst, E. J., Guilliams, T., Wellens, J., O'Day, E. M., Waudby, C. A., Meehan, S., Dumoulin, M., Hsu, S.-T. D., Cremades, N., Verschueren, K. H. G., et al. (2010) · Journal of Molecular Biology · doi:10.1016/j.jmb.2010.07.001 · Cited by 186
Clausen, T. M., Christoffersen, S., Dahlbäck, M., Langkilde, A. E., Jensen, K. E., Resende, M., Agerbæk, M. Ø., Andersen, D., Berisha, B., Ditlev, S. B., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.348839 · Cited by 173
Self-citationTrimnell, A. R., Kraemer, S. M., Mukherjee, S., Phippard, D. J., Janes, J. H., Flamoe, E., Su, X.-Z., Awadalla, P., & Smith, J. D. (2006) · Molecular and Biochemical Parasitology · doi:10.1016/j.molbiopara.2006.03.012 · Cited by 165 · cited 1×
“VAR2CSA is a large protein (,350 kDa) consisting of six Duffy-Binding-Like domains and several inter domains [8,9].”
Achur, R. N., Valiyaveettil, M., Alkhalil, A., Ockenhouse, C. F., & Gowda, D. C. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m006398200 · Cited by 160 · cited 1×
“falciparum-infected erythrocytes (IE) accumulate in the placenta by adhering to chondroitin sulfate A (CSA) chains on chondroitin sulfate proteoglycans (CSPG) in the intervillous spaces and on the microvillous membrane of the placental syncytiotrophoblast [1].”
Hmila, I., Abderrazek, R. B., Saerens, D., Benlasfar, Z., Conrath, K., Ayeb, M. E., Muyldermans, S., & Bouhaouala‐Zahar, B. (2008) · Molecular Immunology · doi:10.1016/j.molimm.2008.04.011 · Cited by 144 · cited 1×
“The VHH gene fragment (600 bp) was separated from the VH genes (900 bp) by agarose gel extraction and re-amplified with the framework-1 and framework4 primers [35] in order to introduce PstI and NotI restriction sites.”
Disulfide Bond Introduction for General Stabilization of Immunoglobulin Heavy-Chain Variable Domains
Saerens, D., Conrath, K., Govaert, J., & Muyldermans, S. (2008) · Journal of Molecular Biology · doi:10.1016/j.jmb.2008.01.022 · Cited by 142
Khunrae, P., Dahlbäck, M., Nielsen, M. A., Andersen, G., Ditlev, S. B., Resende, M., Pinto, V. V., Theander, T. G., Higgins, M. K., & Salanti, A. (2010) · Journal of Molecular Biology · doi:10.1016/j.jmb.2010.01.040 · Cited by 121
Self-citationBockhorst, J., Lu, F., Janes, J. H., Keebler, J., Gamain, B., Awadalla, P., Su, X.-Z., Samudrala, R., Jojic, N., & Smith, J. D. (2007) · Molecular and Biochemical Parasitology · doi:10.1016/j.molbiopara.2007.06.007 · Cited by 117 · cited 1×
“Even though VAR2CSA is conserved relative to other PfEMP1 proteins, there is a substantial sequence variation [10].”
Barfod, L., Bernasconi, N. L., Dahlbäck, M., Jarrossay, D., Andersen, P. H., Salanti, A., Ofori, M. F., Turner, L., Resende, M., Nielsen, M. A., et al. (2007) · Molecular Microbiology · doi:10.1111/j.1365-2958.2006.05503.x · Cited by 110 · cited 1×
“We have extensively explored the naturally-acquired response to VAR2CSA in order to differentiate the protective adhesionblocking response from the immuno-dominant, non-functional response focused towards the DBL3X, DBL5e and DBL6e domains of VAR2CSA [21,22].”
Self-citationNielsen, M. A., Pinto, V. V., Resende, M., Dahlbäck, M., Ditlev, S. B., Theander, T. G., & Salanti, A. (2009) · Infection and Immunity · doi:10.1128/iai.00159-09 · Cited by 92 · cited 1×
“These domains were produced using a baculo-virus expression system, as described in [11,20].”
Self-citationCham, G. K. K., Turner, L., Kurtis, J. D., Mutabingwa, T. K., Fried, M., Jensen, A. T. R., Lavstsen, T., Hviid, L., Duffy, P. E., & Theander, T. G. (2010) · Infection and Immunity · doi:10.1128/iai.00593-10 · Cited by 86 · cited 1×
“In malaria endemic areas, children develop clinical immunity through the acquisition of a broad repertoire of anti-PfEMP1 antibodies [3].”
Self-citationThe Chondroitin Sulfate A-binding Site of the VAR2CSA Protein Involves Multiple N-terminal Domains
Dahlbäck, M., Jørgensen, L. M., Nielsen, M. A., Clausen, T. M., Ditlev, S. B., Resende, M., Pinto, V. V., Arnot, D. E., Theander, T. G., & Salanti, A. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.191510 · Cited by 85 · cited 1×
“The Nbs were subsequently screened against individual VAR2CSA domains (DBL1-6) and against the ID1–ID2a region, which represents the minimal-CSA binding region of VAR2CSA [18,20] (Figure 3).”
Self-citationBoeuf, P., Aitken, E. H., Chandrasiri, U., Chua, C. L. L., McInerney, B., McQuade, L., Duffy, M., Molyneux, M., Brown, G., Glazier, J., et al. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003153 · Cited by 83
Self-citationStructural insight into epitopes in the pregnancy-associated malaria protein VAR2CSA
Andersen, P., Nielsen, M. A., Resende, M., Rask, T. S., Dahlbäck, M., Theander, T., Lund, O., & Salanti, A. (2008) · PLoS Pathogens · doi:10.1371/journal.ppat.0040042 · Cited by 79 · cited 1×
“VAR2CSA is a large protein (,350 kDa) consisting of six Duffy-Binding-Like domains and several inter domains [8,9].”
Self-citationVar2CSA minimal CSA binding region is located within the N-terminal region
Srivastava, A., Gangnard, S., Dechavanne, S., Amirat, F., Lewit Bentley, A., Bentley, G. A., & Gamain, B. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020270 · Cited by 76
Stijlemans, B., Caljon, G., Natesan, S. K. A., Saerens, D., Conrath, K., Pérez-Morga, D. L., Skepper, J. N., Nikolaou, A., Brys, L., Pays, É., et al. (2011) · PLoS Pathogens · doi:10.1371/journal.ppat.1002072 · Cited by 66 · cited 1×
“Stijlemans [36]) was added for 1 h (non-commercial; diluted 1:2000 in 1% skim milk in PBS.”
Self-citationTutterrow, Y. L., Avril, M., Singh, K., Long, C. A., Leke, R. J., Sama, G., Salanti, A., Smith, J. D., Leke, R. G. F., & Taylor, D. W. (2012) · Infection and Immunity · doi:10.1128/iai.00071-12 · Cited by 65
Self-citationBarfod, L., Dobrilovic, T., Magistrado, P., Khunrae, P., Viwami, F., Bruun, J., Dahlbäck, M., Bernasconi, N. L., Fried, M., John, D., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1002390 · Cited by 62
Self-citationMagistrado, P. A., Minja, D., Doritchamou, J., Tuikue Ndam, N., John, D., Schmiegelow, C., Massougbodji, A., Dahlbäck, M., Ditlev, S. B., Pinto, V. V., et al. (2011) · Vaccine · doi:10.1016/j.vaccine.2010.10.080 · Cited by 49
Self-citationFernandez, P., Viebig, N. K., Dechavanne, S., Lépolard, C., Gysin, J., Scherf, A., & Gamain, B. (2008) · Malaria Journal · doi:10.1186/1475-2875-7-170 · Cited by 43
Multilaboratory Approach to Preclinical Evaluation of Vaccine Immunogens for Placental Malaria
Fried, M., Avril, M., Chaturvedi, R., Fernandez, P., Lograsso, J., Narum, D., Nielsen, M. A., Oleinikov, A. V., Resende, M., Salanti, A., et al. (2013) · Infection and Immunity · doi:10.1128/iai.01106-12 · Cited by 38
Self-citationFernandez, P., Petres, S., Mécheri, S., Gysin, J., & Scherf, A. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012558 · Cited by 36
Avril, M., Cartwright, M. M., Hathaway, M. J., & Smith, J. D. (2011) · Malaria Journal · doi:10.1186/1475-2875-10-36 · Cited by 35
Nielsen, M. A., Resende, M., Alifrangis, M., Turner, L., Hviid, L., Theander, T. G., & Salanti, A. (2007) · Experimental Parasitology · doi:10.1016/j.exppara.2007.03.002 · Cited by 33
Self-citationObiakor, H., Avril, M., MacDonald, N. J., Srinivasan, P., Reiter, K., Anderson, C., Holmes, K. L., Fried, M., Duffy, P. E., Smith, J. D., et al. (2013) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00638-12 · Cited by 22
Neutralization of Human Papillomavirus by Specific Nanobodies Against Major Capsid Protein L1
Minaeian, S. (2012) · Journal of Microbiology and Biotechnology · doi:10.4014/jmb.1112.12001 · Cited by 16
Cited by
Xie, Y. J., Dougan, M., Jailkhani, N., Ingram, J., Fang, T., Kummer, L., Momin, N., Pishesha, N., Rickelt, S., Hynes, R. O., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1817147116 · Cited by 296
Vasopressors for hypotensive shock
Gamper, G., Havel, C., Arrich, J., Losert, H., Pace, N. L., Müllner, M., & Herkner, H. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003709.pub4 · Cited by 239
Antigen recognition by single-domain antibodies: structural latitudes and constraints
Henry, K. A., & MacKenzie, C. R. (2018) · mAbs · doi:10.1080/19420862.2018.1489633 · Cited by 109
“Likewise, Ditlev et al.70 attributed the binding of a panel of alpaca VHHs to multiple domains of themalarial VAR2CSAprotein to an inherent ability of VHHs to recognize subdominant epitopes, although limited understanding of the human conventional antibody response against VAR2CSA as well as irreproducibility of these…”
BackgroundZhu, M., Gong, X., Hu, Y., Ou, W., & Wan, Y. (2014) · Journal of Translational Medicine · doi:10.1186/s12967-014-0352-5 · Cited by 96
“However, the conventional method is to subclone the VHH fragment from the phagemid into an expression plasmid [27].”
BackgroundMethodDesigning a VAR2CSA-based vaccine to prevent placental malaria
Fried, M., & Duffy, P. E. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.10.011 · Cited by 86
“Oleinikov et al. [42] reported significantly higher levels f antibodies to DBL1, DBL3 and DBL6 (but not DBL4 or DBL5) n multigravidae compared to primigravidae living in a malaria oloendemic area of Tanzania.”
BackgroundInfluential
Metadata
- Authors
- Ditlev, S. B., Florea, R., Nielsen, M. A., Theander, T. G., Magez, S., Boeuf, P., & Salanti, A.
- Affiliations
- University of Copenhagen (DK)
- Vrije Universiteit Brussel (BE)
- The Royal Melbourne Hospital (AU)
- Corresponding author
- Ditlev, Sisse B.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-01-21
- Volume
- 9
- Issue
- 1
- Pages
- e84981
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3897377
- OpenAlex
- W2043051805
- Cited by
- 31
- References
- 37
- Citations by year
- 2026: 3 · 2024: 1 · 2023: 2 · 2022: 1 · 2021: 4 · 2020: 2 · 2019: 2 · 2018: 3 · 2017: 2 · 2016: 4 · 2015: 2 · 2014: 5
- FWCI
- 4.31
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Funders
- Højteknologifonden
- Agentschap voor Innovatie door Wetenschap en Technologie
- Novo Nordisk
- Novo Nordisk Fonden
- National Health and Medical Research Council (1003384)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Malaria Research and Control
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Health Sciences › Medicine › Hematology › Blood groups and transfusion
- Keywords
- VAR2CSA, placental malaria, Plasmodium falciparum, chondroitin sulfate A, nanobodies, VHH, heavy-chain antibodies, epitope mapping, infected erythrocyte adhesion, placenta, conformational epitopes
- MeSH terms
- Amino Acid Sequence, Animals, Epitopes, Antigens, Protozoan, Camelids, New World, Chondroitin Sulfates, Erythrocytes, Humans, Immunoglobulin Heavy Chains, Molecular Sequence Data, Plasmodium falciparum, Protein Binding, Recombinant Proteins, Sequence Alignment, Malaria, Falciparum, Peptide Library, Single-Domain Antibodies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.